drugset / Trial / NCT03758625
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure
Phase 1
Completed
40 enrolled
Sharon Riddler
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will be done in people living with HIV to see if an investigational vaccine made from a person's own white blood cells is safe and tolerated. This study will also look at the body's immune response to the vaccine and evaluate four different methods of making the vaccine to see which method may result in better immune responses.
Timeline
- Start
- 2019-01-02
- Primary completion
- 2025-02-19
- Completion
- 2025-02-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | a1DC + conserved HIV peptides | Vaccine | 1e+07 cells | — |
| Subject | a1DC + inactivated whole autologous HIV | Vaccine | 1e+07 cells | — |
| Comparator | a1DC + no antigen | Vaccine | 1e+07 cells | — |
| Subject | pgDC + conserved HIV peptides | Vaccine | 1e+07 cells | — |
| Subject | pgDC + inactivated whole autologous HIV | Vaccine | 1e+07 cells | — |
| Comparator | pgDC + no antigen | Vaccine | 1e+07 cells | — |